Clinical trial
A Randomized, Double-Blind, Placebo-controlled Study of Supaglutide on the Safety, Pharmacokinetics and Pharmacodynamics, and Efficacy in Chinese Patients With Type 2 Diabetes.
NCT04314622 is registered in ClinicalTrials.gov with Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Placebo-controlled Study of Supaglutide on the Safety, Pharmacokinetics and Pharmacodynamics, and Efficacy in Chinese Patients With Type 2 Diabetes.
- Lead sponsor
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 14, 2020
- Completion date
- March 16, 2021
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.